Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | TEK | Q02763 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 4/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20311336 | 0.84 | ACVR1 (0.42) | PTPN11ACVR1CDK2CCNE1HSF1 | |
| SCHEMBL1992323 | 0.82 | CDK2 (0.43) | PTPN11MAP4K4ACVR1CDK2CCNE1 | |
| SCHEMBL25085650 | 0.80 | ACVR1 (0.38) | PTPN11ACVR1CDK2CCNE1HSF1 | |
| SCHEMBL21267364 | 0.80 | CDK4 (0.40) | PTPN11ACVR1CDK2CCNE1HSF1 | |
| SCHEMBL28097122 | 0.79 | CYP3A4 (0.46) | PTPN11MAP4K4ACVR1CDK2CCNE1 | |
| SCHEMBL14307264 | 0.78 | ACVR1 (0.46) | ACVR1CDK2CCNE1HSF1CTSC | |
| SCHEMBL19490771 | 0.78 | CDK4 (0.38) | PTPN11ACVR1CDK2CCNE1HSF1 | |
| SCHEMBL28611481 | 0.76 | L3MBTL3 (0.42) | PTPN11ACVR1L3MBTL3CDK4CDK6 | |
| SCHEMBL1976516 | 0.76 | CHRNB2 (0.55) | ACVR1CDK2CCNE1HSF1CTSC | |
| SCHEMBL12558175 | 0.76 | CHRNB2 (0.52) | PTPN11CDK2CCNE1HSF1CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113549069-A | Kinase inhibitor | 重庆复创医药研究有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-108779117-B | Kinase inhibitor | 重庆复创医药研究有限公司 | 2021-08-31 | — | — | CN | disclosed |
| EP-3091008-B1 | KINASE INHIBITOR AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| EP-3091008-B1 | KINASE INHIBITOR AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| US-9949976-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-9949976-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-9949976-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20180000819-A1 | KINASE INHIBITOR AND USE THEREOF | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2018-01-04 | — | — | US | disclosed |
| US-20180000819-A1 | KINASE INHIBITOR AND USE THEREOF | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2018-01-04 | — | — | US | disclosed |
| US-9796701-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-10-24 | — | — | US | disclosed |
| US-9796701-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-10-24 | — | — | US | disclosed |
| US-9796701-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-10-24 | — | — | US | disclosed |
| WO-2017114351-A1 | CERTAIN PROTEIN KINASE INHIBITORS | Chongqing Fochon Pharmaceutical Co., Ltd. (CN) | 2017-07-06 | — | — | WO | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| EP-3091008-A1 | KINASE INHIBITOR AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015101293-A1 | KINASE INHIBITOR AND USE THEREOF | 山东轩竹医药科技有限公司 | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | CDK4, CDK6, CDK3 | PTPN11 1010/4885MAP4K4 160/4885ACVR1 2177/4885 |
| US-20180000819-A1 | KINASE INHIBITOR AND USE THEREOF | CDK4, CDK6, CDK3 | PTPN11 1010/4885MAP4K4 160/4885ACVR1 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.